CDE Detailed Report
Disease: Sickle Cell Disease
Sub-Domain: Assessments and Examinations
CRF: Immune Function Form
Sub-Domain: Assessments and Examinations
CRF: Immune Function Form
| CDE ID | CDE Name | Variable Name | Definition | Short Description | Additional Notes (Question Text) | Permissible Values | Description | Data Type | Disease Specific Instructions | Disease Specific Reference | Population | Classification (e.g., Core) | Version Number | Version Date | CRF Name (CRF Module / Guideline) | Sub Domain Name | Domain Name | Size | Input Restrictions | Min Value | Max Value | Measurement Type | Source | Form Set | Form | Field | Domain | CDASH Variable | CDASH Definition | CDASH Label | Controlled Terminology | Prompt | Essentiality | Question Text | CDASH imp guidance | SDTM IG target | csDSR | PhenX | Data Type | CRF Completion Inst | SDTMIG Target Var | SDTMIG Target Map | Codelist Name | PVs | Pre Pop Value | Query Display | List Style |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C59970 | Platelet count not tested status | PlateletCtNotTestedStatus | Status indicating that the subject/participant's platelet count was not tested. | Status indicating that the subject/participant's platelet count was not tested. | Platelets | Not tested | Not tested | Alphanumeric |
Report findings prior to any first treatment of the primary disease for which the HSCT is being performed. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 13:50:15.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 15: Not tested | ||||||||||||||||||||||||||
| C60066 | Bone abnormality prominent indicator | BoneAbnormalityPromnntInd | Indicator of whether the bone abnormalities the subject/participant presents with are a prominent clinical feature. | Indicator of whether the bone abnormalities the subject/participant presents with are a prominent clinical feature. | If present, are bone abnormalities prominent? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-03 15:35:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 92 | |||||||||||||||||||||||||||
| C60002 | Lymphocyte CD56 count unit of measure | LymphocyteCD56CountUOM | Unit of measure pertaining to the count of CD56 lymphocytes (natural killer (NK) cells) being reported. | Unit of measure pertaining to the count of CD56 lymphocytes (natural killer (NK) cells) being reported. | CD56 (natural killer (NK) cells): specify units | x 10^9 cells per liter (x 10^3 cells per cubic millimeter);x 10^6 cells per liter;Not tested | x 10^9 cells per liter (x 10^3 cells per cubic millimeter);x 10^6 cells per liter;Not tested | Alphanumeric |
Specify the following lymphocyte analyses performed prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 09:41:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 33. Specify units | ||||||||||||||||||||||||||
| C60034 | Meningitis encephalitis infectious organism 3 code | MeningtsEncephltsInfctOrg3Code | Code specifying the third infectious organism pertaining to the subject/participant's meningitis or encephalitis that was identified. | Code specifying the third infectious organism pertaining to the subject/participant's meningitis or encephalitis that was identified. | Meningitis / encephalitis Third organism | 121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509 | Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified | Numeric Values |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved. | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:41:44.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 60 | |||||||||||||||||||||||||
| C59981 | Immunoglobulin E before treatment measurement | IgEBeforeTxMeasr | Measurement in international units per milliliter (IU/mL) of the subject/participant's immunoglobulin E (IgE) prior to any disease treatment. | Measurement in international units per milliliter (IU/mL) of the subject/participant's immunoglobulin E (IgE) prior to any disease treatment. | IgE: IU/mL | Numeric Values |
Specify the following quantitative immunoglobulins measured prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 15:47:39.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Free-Form Entry |
International units per milliliter (IU/mL) | CIBMTR | n/a | Form 2031 revision 2 | 22: Value | |||||||||||||||||||||||||||
| C60077 | Neutropenia prominent indicator | NeutropeniaPromnntInd | Indicator of whether the neutropenia the subject/participant presents with is a prominent clinical feature. | Indicator of whether the neutropenia the subject/participant presents with is a prominent clinical feature. | If present, is neutropenia prominent? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-03 15:35:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 118 | |||||||||||||||||||||||||||
| C60013 | Antibody isohemagglutinin anti-B response status | AbdyIshmgltninAntiBRspStat | Status of the antibody response for isohemagglutinin anti-B. | Status of the antibody response for isohemagglutinin anti-B. | Isohemagglutinin anti-B | Absent;Low;Normal;Not tested | Absent;Low;Normal;Not tested | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 10:36:04.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 40 | |||||||||||||||||||||||||||
| C60045 | Diarrhea severe protracted infectious organism 2 code | DiarheaSevrPrtrctInfctOrg2Code | Code specifying the second infectious organism pertaining to the subject/participant's severe or protracted diarrhea that was identified. | Code specifying the second infectious organism pertaining to the subject/participant's severe or protracted diarrhea that was identified. | Severe or protracted diarrhea Second organism | 121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509 | Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified | Numeric Values |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved. | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:41:44.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 71 | |||||||||||||||||||||||||
| C60056 | Other infection organism 1 code | OtherInfectOrganism1Code | Code specifying the first organism pertaining to the subject/participant's other infection that was identified. | Code specifying the first organism pertaining to the subject/participant's other infection that was identified. | Other infection First organism | 121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509 | Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified | Numeric Values |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved. | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:41:44.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 82 | |||||||||||||||||||||||||
| C59992 | Lymphocyte CD4 measurement | LymphocyteCD4Measr | Measurement of CD4 lymphocytes (T helper cells). | Measurement of CD4 lymphocytes (T helper cells). | CD4 (T helper cells): % or value | Numeric Values |
Specify the following lymphocyte analyses performed prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 09:33:19.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Free-Form Entry |
CIBMTR | n/a | Form 2031 revision 2 | 30 | ||||||||||||||||||||||||||||
| C60024 | Lymphocyte function tetanus antigen status | LymphcytFncTetanusAntigenStat | Status of tetanus antigen lymphocyte function. | Status of tetanus antigen lymphocyte function. | Tetanus antigen | Absent;Low;Normal;Not tested | < 10% of control;10-30% of control;> 30% of control;Not tested | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:19:00.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 50 | |||||||||||||||||||||||||||
| C59960 | White blood cell count not tested status | WBCCtNotTestedStatus | Status indicating that the subject/participant's white blood cell (WBC) count was not tested. | Status indicating that the subject/participant's white blood cell (WBC) count was not tested. | WBC: | Not tested | Not tested | Alphanumeric |
Report findings prior to any first treatment of the primary disease for which the HSCT is being performed. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 13:50:15.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 10: Not tested | ||||||||||||||||||||||||||
| C59971 | Transfusion platelet within 7 days test date status | TrnsfusPlatltWin7DyTstDtStatus | Status indicating that the subject/participant received a transfusion of platelets within 7 days of the pertinent test date. | Status indicating that the subject/participant received a transfusion of platelets within 7 days of the pertinent test date. | Transfused platelets < 7 days from date of test | Transfused platelets < 7 days from date of test | Transfused platelets < 7 days from date of test | Alphanumeric |
Report findings prior to any first treatment of the primary disease for which the HSCT is being performed. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 14:15:25.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 15: transfused platelets | ||||||||||||||||||||||||||
| C60067 | Edema prominent indicator | EdemaPromnntInd | Indicator of whether the edema the subject/participant presents with is a prominent clinical feature. | Indicator of whether the edema the subject/participant presents with is a prominent clinical feature. | If present, is edema prominent? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-03 15:35:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 94 | |||||||||||||||||||||||||||
| C60003 | Lymphocyte CD4 CD45RA measurement type | LymphocyteCD4CD45RAMeasrTyp | Type of measurement of CD4+/CD45RA+ lymphocytes (naive T cells) represented by the recorded value. | Type of measurement of CD4+/CD45RA+ lymphocytes (naive T cells) represented by the recorded value. | CD4+ / CD45RA+ (naive T cells): % or value | Value;Percent of total lymphocytes | Value;Percent of total lymphocytes | Alphanumeric |
Specify the following lymphocyte analyses performed prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 17:52:17.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 34 | ||||||||||||||||||||||||||
| C60035 | Meningitis encephalitis infectious organism code other text | MenngtsEncphltsInfctOrgCodeOTH | The free-text field related to 'Meningitis encephalitis infectious organism 1 code', 'Meningitis encephalitis infectious organism 2 code', or 'Meningitis encephalitis infectious organism 3 code', specifying other text. | The free-text field related to 'Meningitis encephalitis infectious organism 1 code', 'Meningitis encephalitis infectious organism 2 code', or 'Meningitis encephalitis infectious organism 3 code', specifying other text. | Meningitis / encephalitis Specify other organism | Alphanumeric |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 14:17:24.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers | 255 |
Free-Form Entry |
CIBMTR | n/a | Form 2031 revision 2 | 61 | |||||||||||||||||||||||||||
| C59982 | Immunoglobulin E not tested status | IgENotTestedStatus | Status indicating that the subject/participant's immunoglobulin E (IgE) was not tested. | Status indicating that the subject/participant's immunoglobulin E (IgE) was not tested. | IgE: | Not tested | Not tested | Alphanumeric |
Specify the following quantitative immunoglobulins measured prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 13:50:15.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 23: Not tested | ||||||||||||||||||||||||||
| C60078 | Skin rash prominent indicator | SkinRashPromnntInd | Indicator of whether the skin rash the subject/participant presents with is a prominent clinical feature. | Indicator of whether the skin rash the subject/participant presents with is a prominent clinical feature. | If present, is skin rash prominent? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-03 15:35:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 120 | |||||||||||||||||||||||||||
| C60014 | Antibody protein conjugated HIB pneumococcal vaccine response status | AbdyPtnCnjHIBPneuVaccRspStat | Status of the antibody response for protein conjugated HIB or pneumococcal vaccine. | Status of the antibody response for protein conjugated HIB or pneumococcal vaccine. | Protein conjugated HIB or pneumococcal vaccine | Absent;Low;Normal;Not tested | Absent;Low;Normal;Not tested | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 10:36:04.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 41 | |||||||||||||||||||||||||||
| C60046 | Diarrhea severe protracted infectious organism 3 code | DiarheaSevrPrtrctInfctOrg3Code | Code specifying the third infectious organism pertaining to the subject/participant's severe or protracted diarrhea that was identified. | Code specifying the third infectious organism pertaining to the subject/participant's severe or protracted diarrhea that was identified. | Severe or protracted diarrhea Third organism | 121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509 | Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified | Numeric Values |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved. | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:41:44.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 72 | |||||||||||||||||||||||||
| C60057 | Other infection organism 2 code | OtherInfectOrganism2Code | Code specifying the second organism pertaining to the subject/participant's other infection that was identified. | Code specifying the second organism pertaining to the subject/participant's other infection that was identified. | Other infection Second organism | 121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509 | Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified | Numeric Values |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved. | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:41:44.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 83 | |||||||||||||||||||||||||
| C59993 | Lymphocyte CD4 count unit of measure | LymphocyteCD4CountUOM | Unit of measure pertaining to the count of CD4 lymphocytes (T helper cells) being reported. | Unit of measure pertaining to the count of CD4 lymphocytes (T helper cells) being reported. | CD4 (T helper cells): specify units | x 10^9 cells per liter (x 10^3 cells per cubic millimeter);x 10^6 cells per liter;Not tested | x 10^9 cells per liter (x 10^3 cells per cubic millimeter);x 10^6 cells per liter;Not tested | Alphanumeric |
Specify the following lymphocyte analyses performed prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 09:41:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 30. Specify units | ||||||||||||||||||||||||||
| C60025 | Hepatitis present indicator | HepatitisPresentInd | Indicator of whether hepatitis is present in the subject/participant. | Indicator of whether hepatitis is present in the subject/participant. | Hepatitis Site of Infection? | No;Yes | No;Yes | Alphanumeric |
Infections Identified between Diagnosis and the Start of the Preparative Regimen. Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:38:10.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 51. Site of infection? | ||||||||||||||||||||||||||
| C59961 | Lymphocyte not tested status | LymphocyteNotTestedStatus | Status indicating that the subject/participant's lymphocytes were not tested. | Status indicating that the subject/participant's lymphocytes were not tested. | Lymphocytes | Not tested | Not tested | Alphanumeric |
Report findings prior to any first treatment of the primary disease for which the HSCT is being performed. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 13:50:15.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 11: Not tested | ||||||||||||||||||||||||||
| C59972 | Immunoglobulin G before treatment value | IgGBeforeTxVal | Value of the subject/participant's immunoglobulin G (IgG) measurement prior to any disease treatment. | Value of the subject/participant's immunoglobulin G (IgG) measurement prior to any disease treatment. | IgG: | Numeric Values |
Specify the following quantitative immunoglobulins measured prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 15:47:39.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Free-Form Entry |
CIBMTR | n/a | Form 2031 revision 2 | 16: Value | ||||||||||||||||||||||||||||
| C60068 | Eosinophilia prominent indicator | EosinophiliaPromnntInd | Indicator of whether the eosinophilia the subject/participant presents with is a prominent clinical feature. | Indicator of whether the eosinophilia the subject/participant presents with is a prominent clinical feature. | If present, is eosinophilia prominent? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-03 15:35:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 96 | |||||||||||||||||||||||||||
| C60004 | Lymphocyte CD4 CD45RA measurement | LymphocyteCD4CD45RAMeasr | Measurement of CD4+/CD45RA+ lymphocytes (naive T cells). | Measurement of CD4+/CD45RA+ lymphocytes (naive T cells). | CD4+ / CD45RA+ (naive T cells): % or value | Numeric Values |
Specify the following lymphocyte analyses performed prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 09:33:19.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Free-Form Entry |
CIBMTR | n/a | Form 2031 revision 2 | 34 | ||||||||||||||||||||||||||||
| C60036 | Meningitis encephalitis prominent feature ID indicator | MeningtsEncephltsPromFeatIDInd | Indicator of whether meningitis or encephalitis was a prominent feature of the subject/participant's ID. | Indicator of whether meningitis or encephalitis was a prominent feature of the subject/participant's ID. | If meningitis / encephalitis was present, was it a prominent feature of ID? | No;Yes | No;Yes | Alphanumeric |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 14:22:19.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 62 | ||||||||||||||||||||||||||
| C59983 | Immunoglobulin supplemental intravenous prior ID first treatment indicator | IGSupplIVPriorID1stTxInd | Indicator of whether the subject/participant received supplemental intravenous immunoglobulins (IVIG) prior to any first treatment of (ID). | Indicator of whether the subject/participant received supplemental intravenous immunoglobulins (IVIG) prior to any first treatment of (ID). | Did the recipient receive supplemental intravenous immunoglobulins (IVIG) prior to any first treatment of ID? | No;Yes;Unknown | No;Yes;Unknown | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 16:29:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 24. | |||||||||||||||||||||||||||
| C60079 | Thrombocytopenia prominent indicator | ThrombocytopeniaPromnntInd | Indicator of whether the thrombocytopenia (< 100 x 10^9/liter) the subject/participant presents with is a prominent clinical feature. | Indicator of whether the thrombocytopenia (< 100 x 10^9/liter) the subject/participant presents with is a prominent clinical feature. | If present, is thrombocytopenia (< 100 x 10^9/L) prominent? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-03 15:35:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 122 | |||||||||||||||||||||||||||
| C60015 | Antibody tetanus response status | AbdyTetanusRspStat | Status of the antibody response for tetanus. | Status of the antibody response for tetanus. | Tetanus | Absent;Low;Normal;Not tested | Absent;Low;Normal;Not tested | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 10:36:04.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 42 | |||||||||||||||||||||||||||
| C60047 | Diarrhea severe protracted infectious organism code other text | DiarheaSvrPrtrctInfctOrg3CdOTH | The free-text field related to 'Diarrhea severe protracted infectious organism 1 code', 'Diarrhea severe protracted infectious organism 2 code', or 'Diarrhea severe protracted infectious organism 3 code', specifying other text. | The free-text field related to 'Diarrhea severe protracted infectious organism 1 code', 'Diarrhea severe protracted infectious organism 2 code', or 'Diarrhea severe protracted infectious organism 3 code', specifying other text. | Severe or protracted diarrhea Specify other organism | Alphanumeric |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 14:17:24.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers | 255 |
Free-Form Entry |
CIBMTR | n/a | Form 2031 revision 2 | 73 | |||||||||||||||||||||||||||
| C60058 | Other infection organism 3 code | OtherInfectOrganism3Code | Code specifying the third organism pertaining to the subject/participant's other infection that was identified. | Code specifying the third organism pertaining to the subject/participant's other infection that was identified. | Other infection Third organism | 121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509 | Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified | Numeric Values |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved. | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:41:44.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 84 | |||||||||||||||||||||||||
| C59994 | Lymphocyte CD8 measurement type | LymphocyteCD8MeasurementTyp | Type of measurement of CD8 lymphocytes (cytotoxic T cells) represented by the recorded value. | Type of measurement of CD8 lymphocytes (cytotoxic T cells) represented by the recorded value. | CD8 (cytotoxic T cells): % or value | Value;Percent of total lymphocytes | Value;Percent of total lymphocytes | Alphanumeric |
Specify the following lymphocyte analyses performed prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 17:52:17.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 31 | ||||||||||||||||||||||||||
| C60026 | Hepatitis infectious organism 1 code | HepatitisInfectOrganism1Code | Code specifying the first infectious organism pertaining to the subject/participant's hepatitis that was identified. | Code specifying the first infectious organism pertaining to the subject/participant's hepatitis that was identified. | Hepatitis First organism | 121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509 | Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified | Numeric Values |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved. | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:41:44.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 52 | |||||||||||||||||||||||||
| C59962 | Eosinophil not tested status | EosinophilNotTestedStatus | Status indicating that the subject/participant's eosinophils were not tested. | Status indicating that the subject/participant's eosinophils were not tested. | Eosinophils | Not tested | Not tested | Alphanumeric |
Report findings prior to any first treatment of the primary disease for which the HSCT is being performed. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 13:50:15.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 12: Not tested | ||||||||||||||||||||||||||
| C59973 | Immunoglobulin G pre-defined unit of measure | IgGPreDefUOM | Unit of measurement specifying the pre-defined unit pertaining to the reported immunoglobulin G (IgG) value. | Unit of measurement specifying the pre-defined unit pertaining to the reported immunoglobulin G (IgG) value. | IgG: | grams per deciliter;grams per liter;milligrams per deciliter | grams per deciliter (g/dL);grams per liter (g/L);milligrams per deciliter (mg/dL) | Alphanumeric |
Specify the following quantitative immunoglobulins measured prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 15:51:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 16: Specify units | ||||||||||||||||||||||||||
| C60069 | Failure to thrive prominent indicator | FailurToThrivePromnntInd | Indicator of whether the failure to thrive (weight < 5th percentile) the subject/participant presents with is a prominent clinical feature. | Indicator of whether the failure to thrive (weight < 5th percentile) the subject/participant presents with is a prominent clinical feature. | If present, is the failure to thrive (weight < 5th percentile) prominent? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-03 15:35:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 98 | |||||||||||||||||||||||||||
| C60005 | Lymphocyte CD4 CD45RA count unit of measure | LymphocyteCD4CD45RACountUOM | Unit of measure pertaining to the count of CD4+/CD45RA+ lymphocytes (naive T cells) being reported. | Unit of measure pertaining to the count of CD4+/CD45RA+ lymphocytes (naive T cells) being reported. | CD4+ / CD45RA+ (naive T cells): specify units | x 10^9 cells per liter (x 10^3 cells per cubic millimeter);x 10^6 cells per liter;Not tested | x 10^9 cells per liter (x 10^3 cells per cubic millimeter);x 10^6 cells per liter;Not tested | Alphanumeric |
Specify the following lymphocyte analyses performed prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 09:41:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 34. Specify units | ||||||||||||||||||||||||||
| C60037 | Pneumonia present indicator | PneumoniaPresentInd | Indicator of whether pneumonia is present in the subject/participant. | Indicator of whether pneumonia is present in the subject/participant. | Pneumonia Site of infection? | No;Yes | No;Yes | Alphanumeric |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:38:10.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 63. Site of infection? | ||||||||||||||||||||||||||
| C59984 | Immunoglobulin supplemental intravenous therapy ongoing within one month immunoglobulin test indicator | IgSplIvThpyOngoWin1MoIgTstInd | Indicator of whether supplemental intravenous immunoglobulin (IVIG) therapy was ongoing within one month of immunoglobulin testing. | Indicator of whether supplemental intravenous immunoglobulin (IVIG) therapy was ongoing within one month of immunoglobulin testing. | Was therapy ongoing within one month of immunoglobulin testing? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 17:29:14.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 25 | |||||||||||||||||||||||||||
| C60080 | Warts prominent indicator | WartsPromnntInd | Indicator of whether the warts the subject/participant presents with are a prominent clinical feature. | Indicator of whether the warts the subject/participant presents with are a prominent clinical feature. | If present, are warts prominent? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-03 15:35:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 124 | |||||||||||||||||||||||||||
| C60016 | Unconjugated pneumococcal polysaccharide serotype produce protective level count | UncnjPneumPlyscSrtypPrdPrtLvCt | Count of serotypes from unconjugated pneumococcal polysaccharide vaccine that have been assessed as producing a protective level in the subject/participant. | Count of serotypes from unconjugated pneumococcal polysaccharide vaccine that have been assessed as producing a protective level in the subject/participant. | Unconjugated pneumococcal polysaccharide: Number of serotypes producing a protective level | Numeric Values | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:00:44.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Free-Form Entry |
CIBMTR | n/a | Form 2031 revision 2 | 43: Number of serotypes | |||||||||||||||||||||||||||||
| C60048 | Diarrhea severe protracted prominent feature ID indicator | DiarrheaSvrPrtrctPromFeatIDInd | Indicator of whether severe or protracted diarrhea was a prominent feature of the subject/participant's ID. | Indicator of whether severe or protracted diarrhea was a prominent feature of the subject/participant's ID. | If diarrhea was present, was it a prominent feature of ID? | No;Yes | No;Yes | Alphanumeric |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 14:22:19.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 74 | ||||||||||||||||||||||||||
| C60059 | Other infection organism code other text | OtherInfectOrganismCodeOTH | The free-text field related to 'Other infection organism 1 code', 'Other infection organism 2 code', or 'Other infection organism 3 code', specifying other text. | The free-text field related to 'Other infection organism 1 code', 'Other infection organism 2 code', or 'Other infection organism 3 code', specifying other text. | Other infection Specify other organism | Alphanumeric |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 14:17:24.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers | 255 |
Free-Form Entry |
CIBMTR | n/a | Form 2031 revision 2 | 85 | |||||||||||||||||||||||||||
| C59995 | Lymphocyte CD8 measurement | LymphocyteCD8Measr | Measurement of CD8 lymphocytes (cytotoxic T cells). | Measurement of CD8 lymphocytes (cytotoxic T cells). | CD8 (cytotoxic T cells): % or value | Numeric Values |
Specify the following lymphocyte analyses performed prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 09:33:19.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Free-Form Entry |
CIBMTR | n/a | Form 2031 revision 2 | 31 | ||||||||||||||||||||||||||||
| C60027 | Hepatitis infectious organism 2 code | HepatitisInfectOrganism2Code | Code specifying the second infectious organism pertaining to the subject/participant's hepatitis that was identified. | Code specifying the second infectious organism pertaining to the subject/participant's hepatitis that was identified. | Hepatitis Second organism | 121;122;123;124;125;126;127;128;129;171;172;113;130;131;132;173;133;101;134;177;135;136;137;138;139;144;145;146;147;102;103;148;149;104;150;151;112;174;110;175;176;105;152;106;153;154;155;156;157;158;159;107;160;161;162;163;164;165;166;167;178;168;169;197;198;501;502;200;201;206;202;207;203;204;205;209;210;211;212;213;219;220;230;261;240;241;242;250;259;260;503;301;302;303;304;305;306;307;308;309;310;323;324;311;312;313;314;315;316;317;318;319;320;321;322;329;504;402;403;404;409;505;509 | Acinetobacter;Actinomyces;Bacillus;Bacteroides (gracillis, uniformis, vulgaris, other species);Bordetella pertussis (whooping cough);Borrelia (Lyme disease);Branhamella or Moraxella catarrhalis (other species);Campylobacter (all species);Capnocytophaga;Chlamydia pneumoniae;Other chlamydia, specify;Chlamydia, NOS;Citrobacter (freundii, other species);Clostridium (all species except difficile);Clostridium difficile;Corynebacterium jeikeium;Corynebacterium (all non-diptheria species);Coxiella;Enterobacter;Enterococcus, vancomycin resistant (VRE);Enterococcus (all species);Escherichia (also E. coli);Flavimonas oryzihabitans;Flavobacterium;Fusobacterium;Haemophilus (all species, including influenzae);Helicobacter pylori;Klebsiella;Lactobacillus (bulgaricus, acidophilus,other species);Legionella;Leptospira;Leptotrichia buccalis;Leuconostoc (all species);Listeria;Methylobacterium;Micrococcus, NOS;Mycobacterium avium– intracellulare (MAC, MAI);Mycobacterium species (cheloneae, fortuitum, haemophilum, kansasii,mucogenicum;Mycobacterium tuberculosis (tuberculosis, Koch bacillus);Other mycobacterium, specify;Mycobacterium, NOS;Mycoplasma;Neisseria (gonorrhoea, meningitidis, other species);Nocardia;Pasteurella multocida;Propionibacterium (acnes, avidum, granulosum, other species);Proteus;Pseudomonas (all species except cepacia & maltophilia);Pseudomonas or Burkholderia cepacia;Pseudomonas or Stenotrophomonas or Xanthomonas maltophilia;Rhodococcus;Rickettsia;Salmonella (all species);Serratia marcescens;Shigella;Staphylococcus, coagulase negative (not aureus);Staphylococcus aureus;Staphylococcus, NOS;Stomatococcus mucilaginosis;Streptococcus (all species except Enterococcus);Streptococcus pneumoniae;Treponema (syphilis);Vibrio (all species);Multiple bacteria at a single site, specify bacterial codes;Other bacteria, specify;Suspected atypical bacterial infection;Suspected bacterial infection;Candida, NOS;Candida albicans;Candida guillermondi;Candida krusei;Candida lusitaniae;Candida parapsilosis;Candida tropicalis;Candida (Torulopsis) glabrata;Other Candida, specify;Aspergillus, NOS;Aspergillus flavus;Aspergillus fumigatus;Aspergillus niger;Other Aspergillus, specify;Cryptococcus species;Fusarium species;Histoplasmosis;Zygomycetes, NOS;Mucormycosis;Rhizopus;Yeast, NOS;Other fungus, specify;Pneumocystis (PCP / PJP);Suspected fungal infection;Herpes simplex (HSV1, HSV2);Varicella (herpes zoster, chicken pox);Cytomegalovirus (CMV);Adenovirus;Enterovirus (coxsackie, echo, polio);Hepatitis A (HAV);Hepatitis B (HBV, Australian antigen);Hepatitis C (HCV);HIV-1 (HTLV-III);Influenza, NOS;Influenza A;Influenza B;Measles (rubeola);Mumps;Progressive multifocalleukoencephalopathy (PML);Respiratory syncytial virus (RSV);Rubella (German measles);Parainfluenza;Human herpesvirus-6 (HHV-6);Epstein-Barr virus (EBV);Polyoma virus (BK virus, JC virus);Rotavirus;Rhinovirus;Human papilloma virus (HPV);Other virus, specify;Suspected viral infection;Toxoplasma;Giardia;Cryptosporidium;Other parasite, specify;Suspected parasite infection;No organism identified | Numeric Values |
Infections Identified between Diagnosis and the Start of the Preparative Regimen: Specify the presence of all clinically significant infections identified between diagnosis and the start of the preparative regimen. Only report an organism once, even if it was identified at the same site in subsequent infections. |
CIBMTR Form 2031 revision 2 June 2009, Copyright © 2009 National Marrow Donor Program and The Medical College of Wisconsin, Inc. All rights reserved. | Adult;Pediatric | Supplemental | 1.00 | 2020-09-02 13:41:44.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 53 | |||||||||||||||||||||||||
| C59963 | Polymorphonuclear leukocyte value | PMNLeukocyteVal | Value (as a percentage of white blood cell (WBC) count) of the subject/participant's polymorphonuclear (PMN) leukocytes. | Value (as a percentage of white blood cell (WBC) count) of the subject/participant's polymorphonuclear (PMN) leukocytes. | Polymorphonuclear leukocytes (PMN): % | Numeric Values |
Report findings prior to any first treatment of the primary disease for which the HSCT is being performed. |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 13:58:31.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Free-Form Entry |
0 | 100 | percent of white blood cells | CIBMTR | n/a | Form 2031 revision 2 | 13: Polymorphonuclear leukocytes (PMN)x | |||||||||||||||||||||||||
| C59974 | Immunoglobulin G not tested status | IgGNotTestedStatus | Status indicating that the subject/participant's immunoglobulin G (IgG) was not tested. | Status indicating that the subject/participant's immunoglobulin G (IgG) was not tested. | IgG: | Not tested | Not tested | Alphanumeric |
Specify the following quantitative immunoglobulins measured prior to any disease treatment: |
Adult;Pediatric | Supplemental | 1.00 | 2020-09-01 13:50:15.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 17: Not tested | ||||||||||||||||||||||||||
| C60070 | Growth hormone deficiency prominent indicator | GrwthHrmoneDeficncyPromnntInd | Indicator of whether the growth hormone deficiency the subject/participant presents with is a prominent clinical feature. | Indicator of whether the growth hormone deficiency the subject/participant presents with is a prominent clinical feature. | If present, is growth hormone deficiency prominent? | No;Yes | No;Yes | Alphanumeric | Adult;Pediatric | Supplemental | 1.00 | 2020-09-03 15:35:46.0 | Immune Function Form | Assessments and Examinations | Laboratory Tests and Biospecimens%2FBiomarkers |
Single Pre-Defined Value Selected |
CIBMTR | n/a | Form 2031 revision 2 | 104 |